Stock Price & Analysis

Based on the recent data and market analysis, here is my assessment of DNA stock:

Technical Analysis

The stock shows significant bearish momentum with:

• Recent close at $10.82, down 5.34% in the last session
• Trading below both 5-day and 10-day moving averages
• Formed a bearish flag pattern after recent decline
• RSI indicating oversold conditions at 31.01

Fundamental Analysis

The company faces several challenges:

• No profitability yet with negative earnings
• High valuation metrics with P/S ratio of 13.07x for 2023 [from Relevant Data]
• Significant cash burn rate requiring additional funding

Recent Developments

• Ginkgo disclosed $70,000 in lobbying efforts for Q4 2024, focusing on government stakeholders about capabilities in wastewater surveillance and biomanufacturing
• Insider trading shows concerning pattern with 12 sales and 0 purchases in past 6 months
• Institutional sentiment appears negative with 219 institutions reducing positions vs only 19 increasing

Market Sentiment

The stock recently received a Strong Buy upgrade from Zacks, however:

• High volatility with 13.38% daily price swings
• Trading volume declining on down days suggesting lack of buying support
• Technical indicators showing continued downward pressure

Recommendation

SELL recommendation based on:

1. Deteriorating technical picture
2. Negative institutional flows
3. Challenging fundamentals and cash burn
4. Insider selling pattern
5. High valuation multiples relative to peers

Based on the provided data and technical analysis, here is the price prediction for DNA stock in 2025:

DNA stock is expected to reach $13.24 (fibonacci pivot) by mid-2025, with potential upside to $15.21 (fibonacci R1) if market conditions remain favorable, driven by improving technical indicators and historical price patterns. The stock's recent consolidation around $10-11 range provides a stable base for this projected move higher.

The S1 support level for DNA Stock is $10.05 ,The R1 resistant level for DNA Stock is $15.04.

As of the end of day on 2025-02-26, the price of DNA Stock was $8.74.

The target price for DNA Stock according to analyst rating is 16.00, with the highest price target at 16.00 and the lowest at 16.00. Analysts have a Moderate Buy rating on DNA Stock overall.

The market cap of DNA is $560.6M.

Based on the technical and fundamental data analysis, here are 5 key points about DNA's valuation:

DNA is currently showing signs of being overvalued at $10.92, trading significantly above its 60-day SMA of $11.04 and 200-day SMA of $12.59.

The stock's RSI readings (RSI-14 at 43.23) indicate neutral momentum but trending towards oversold territory, suggesting potential downside risk.

Institutional sentiment is notably bearish, with 219 institutions reducing positions versus only 19 increasing in the latest quarter, indicating lack of confidence in current valuations.

The stock's Bollinger Band analysis (BBP_20_3 at 0.18) suggests price is near the lower band, but with weak technical support levels.

Recent insider selling activity (12 sales, 0 purchases in past 6 months) combined with declining institutional ownership signals internal pessimism about current valuation levels.

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Based on the available data and market analysis, here's the 2030 price prediction for DNA stock:

Ginkgo Bioworks (DNA) stock is projected to reach $45-50 by 2030, driven by the explosive growth in the DNA synthesis market which is expected to maintain an 18.1% CAGR through 2028. The company's strategic positioning in synthetic biology and expanding partnerships in biomanufacturing support this bullish outlook. However, the stock currently faces near-term volatility with technical indicators showing mixed signals.

DNA has a total of 1218 employees.